Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Sales Increase by 9.9%, Net Profits Return to Black: NBI
May 8, 2012
- OrphanPacific Focuses on Building Detailing Form: President Ichikawa
May 8, 2012
- Eisai US Subsidiary Concludes Research Agreement with UK Venture for Identifying Target Molecules for New Cancer Drugs
May 8, 2012
- Daiichi Sankyo to Aim for Early Market Penetration for Ranmark in Copromotion with AZ
May 7, 2012
- The Growing Presence of Foreign-Affiliates (1)
May 7, 2012
- GSK Files Ofatumumab for Treatment of CLL
May 7, 2012
- DSP Aims to Enhance Its Presence in Field of Oncology by Developing First-in-Class Drugs
May 7, 2012
- MHLW Approves Sanofi Pasteur’s Imovax Polio SC Injection
May 7, 2012
- Astellas Collaborates with US Company in New “Multi-Track R&D Approach”
April 27, 2012
- 90% of Pharmacies Receive Generic Name Prescriptions with Loxoprofen as Most Frequently Prescribed Drug: Survey
April 27, 2012
- DSP Completes Acquisition of BBI, Bolsters Oncology Business
April 27, 2012
- Boehringer Ingelheim to Shift to Independent Marketing in Japan for Upcoming New Products
April 27, 2012
- Seikagaku Terminates Agreement with Finland’s Biotie
April 26, 2012
- Latuda Shows Usefulness for Bipolar I Depression in 2 PIII Clinical Trials: DSP
April 26, 2012
- R-Tech Ueno Completes PI Study for Treatment of Hypotrichosis of the Eyelashes
April 26, 2012
- New COPD Treatment Meets Primary Endpoints in Fourth PIII Trial: Sosei Group
April 26, 2012
- Hisamitsu Fails to Obtain Expected Results in Domestic PIII Study for Tinea Unguium Treatment
April 26, 2012
- Takeda Launches Renal Anemia Drug Omontys in US
April 26, 2012
- 50% of Doctors Obtain Information on New Drugs From MRs: Survey
April 25, 2012
- Generics Aimed for Early Stage Sales of 10 Billion Yen, in the Black for Establishing Base: Daiichi Sankyo Espha President Yoshiwaka
April 25, 2012
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…